ArticleBMC chemistry2025
Use of gold/iron metal-organic framework nanoparticles (AuNPs/FeMOF)-modified glassy carbon electrode as an electrochemical sensor for the quantification of risperidone in patient plasma samples.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Risperidone (RIS) is one of the most prescribed atypical antipsychotics approved for the treatment of various neuropsychiatric diseases. For the correlation of serum concentration and pharmacological effects of RIS, therapeutic drug monitoring is considered a fundamental concept for clinical application. This paper is provided to develop an electrochemical probe for the determination of RIS in biological samples by modification of glassy carbon electrode (GCE) using gold nanoparticles (AuNPs) and iron metal-organic-frameworks (FeMOFs). This probe fabrication process was characterized with various techniques including Fourier transform infrared (FTIR), emission scanning electron microscopy (FESEM), energy dispersive X-ray (EDX), atomic force microscopy (AFM), and dynamic light scattering (DLS) to confirm the proper synthesis of materials and the sensors designing. The developed probe square-wave voltammetry (SWV) signal was linear upon RIS concentration from 0.02 to 50 µg/mL with a low limit of quantification (LOQ) of 0.02 µg/mL. Based on the validated method, high accuracy and precision, good specificity, and suitable stability of fabricated probes were achieved. As the ultimate step, this method was successfully applied for the quantification of RIS in patients' plasma samples with regular RIS consumption. The fabricated electrochemical demonstrates favorable clinical applicability due to its simplicity, high sensitivity, low sample pretreatment time, and rapid analysis time, making it a promising probe as an alternative to current separation-based methods. Also, the developed probe is cost-effective, as it uses a low amount of materials, decreases sample processing time, and utilizes inexpensive materials, which could remarkably reduce the overall cost of RIS concentration detection in clinical samples. The obtained results showed the potential of the developed probe for fast and reliable detection of RIS in plasma samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.